<DOC>
	<DOCNO>NCT00563602</DOCNO>
	<brief_summary>This prospective trial random distribution , open , parallel group , patient esophagic variceal bleed randomized two treatment group , control acute bleeding . All patient receive standard medical therapy b-blockers endoscopic ligation ( LEV ) esophageal varix . The control group assign receive LEV + Nadolol + MNI . The experimental group assign receive treatment accord hemodynamic response . All patient include experimental group receive LEV pharmacological treatment nadolol alone combine MNI Prazosin ( PZ )</brief_summary>
	<brief_title>Treatment Prevention Variceal Rebleeding Guided Hemodynamic Response</brief_title>
	<detailed_description>This prospective trial random distribution , open , parallel group , patient esophagic variceal bleed randomized two treatment group , control acute bleeding . All patient receive standard medical therapy b-blockers endoscopic ligation ( LEV ) esophageal varix . The control group assign receive LEV + Nadolol ( N ) + Isosorbide Mononitrate ( MNI ) The experimental group assign receive treatment accord hemodynamic response . All patient include experimental group receive LEV pharmacological treatment nadolol alone combine MNI Prazosin ( PZ ) A hepatic hemodynamic study perform patient group , baseline ( In basal value acute b-blockers response assess ) , second study 3 rd -4 th week drug therapy start , titration dos . In experimental group , responder acute administration b-blockers receive LEV + Nadolol alone , patient response receive LEV + N + MNI , another hemodynamic study perform 3 rd -4 th week drug therapy start , titration dos , assess response . The non-responders control study switch LEV+ N + PZ , 3erd hemodynamic study perform . Randomization stratify accord degree hepatic insufficiency , assess Child-Pugh classification ( class A B v C )</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Prazosin</mesh_term>
	<mesh_term>Nadolol</mesh_term>
	<mesh_term>Isosorbide-5-mononitrate</mesh_term>
	<mesh_term>Isosorbide Dinitrate</mesh_term>
	<mesh_term>Isosorbide</mesh_term>
	<criteria>All patient admit emergency 1 ) gastrointestinal bleeding due esophageal varix assess endoscopy , include . We define esophagic variceal bleed endoscopic find follow sign : 1 ) active variceal bleed 2 ) clot platelet cluster 3 ) esophageal varix associate red blood esophagogastric lumen absence source bleed . Clinical criterion / analytical , ultrasound / liver biopsy consistent diagnosis liver cirrhosis . Written inform consent participate study . Patients fertile age use barrier method prevent pregnancy entire study . The pregnancy test prior study must negative Age &lt; 18 &gt; 80 year . Patients eligible active treatment due underlie morbid condition ( terminal ) . Here included patient advance liver disfunction ( ChildPugh &gt; ) patient life expectancy &lt; 6 mo . Refuse participate study . Bleeding due cause esophageal varix . Prior inclusion study . Failure control acute bleeding ( index episode ) . Pretreatment elective LEV program , sclerotherapy combine β blocker plus nitrate , portosystemic shunt ( surgical percutaneous ) . Contraindication β blocker MNI ( exclude patient contraindication one drug ) endoscopic procedure . Pregnancy . Presence multiple hepatocellular carcinoma diameter &gt; 5 cm . Portal vein thrombosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Portal hypertension</keyword>
	<keyword>Prevention rebleeding</keyword>
	<keyword>Complications cirrhosis</keyword>
	<keyword>Portal hemodynamic</keyword>
	<keyword>Prazosine</keyword>
	<keyword>Nadolol</keyword>
	<keyword>isosorbide mononitrate</keyword>
</DOC>